MASSDEVICE ON CALL — The embargo breach that got Boston Scientific’s (NYSE:BSX) PREVAIL clinical trial results pulled from the lineup at the American College of Cardiology conference this weekend was "an honest mistake," according to the company, but conference organizers don’t regret canceling the presentation.
ACC organizers followed protocol in scrubbing the presentation after Boston Scientific handed embargoed data to investors ahead of schedule, a move that some doctors considered a true loss for the conference.
""We had no choice – we have to follow procedures," ACC president elect Dr. John Harold told heartwire.
The PREVAIL results were among the top highlights of this year’s ACC meeting and thousands of attendees showed up Saturday morning only to find out that the study had been pulled. Conference-goers were understanding, but upset over the dramatic turn of events.
"I understand the ACC has to follow procedures, but the end result was very unhelpful to all its members who came here this morning to see the results of the study and hear the discussion about them," U.K. cardiologist Dr. Marcus Flather told heartwire.
The top 10 strategies for patient safety
The Agency for Healthcare Research & Quality released its list of the top 10 ways clinicians can promote patient safety, among them reducing urinary catheter use and real-time ultrasonography for central line placement.
Abandon fee-for-service, panel says
The National Commission on Physicians Payment Reform recommended that the U.S. abandon its fee-for-service system for allocating physician payments by the end of the decade.
3D printing for the human skull
Connecticut medical device maker Oxford Performance Materials won FDA clearance for its OsteoFab 3D printed system, the 1st time the federal watchdog agency has cleared a 3D-printed polymer implant.